Oncolytic-adenovirus-expressed RNA interference for cancer therapy

Expert Opin Biol Ther. 2010 Sep;10(9):1331-41. doi: 10.1517/14712598.2010.512002.

Abstract

Importance of the field: RNA interference (RNAi) has generated considerable excitement for its potential cancer therapeutic applications. Because of the difficulties in delivering a large amount of siRNA to cancer cells and the short half-life of siRNA, it is important to choose an efficient delivery system for transduction of siRNA into target cells. Oncolytic adenovirus offers a better platform by virtue of its high transfection efficiency and selective replication in cancer cells.

Areas covered in this review: This review focuses on the synergism between oncolytic adenovirus and siRNA antitumor responses, and discusses recent progresses in oncolytic-adenovirus-expressed siRNA.

What the reader will gain: siRNA-expressing oncolytic adenovirus can generate a significantly enhanced antitumor effect through gene knockdown and viral oncolysis.

Take home message: Due to its potency and target specificity, using siRNA delivery by oncolytic adenovirus has generated much excitement and will open new avenues for treatment of human cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Neoplasms / genetics
  • Neoplasms / therapy*
  • Neoplasms / virology
  • Oncolytic Virotherapy*
  • Oncolytic Viruses / genetics*
  • RNA Interference*
  • RNA, Small Interfering / biosynthesis*

Substances

  • RNA, Small Interfering